{"id":"NCT00684177","sponsor":"GlaxoSmithKline","briefTitle":"Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","officialTitle":"A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2008-05-26","resultsPosted":"2010-08-04","lastUpdate":"2016-11-23"},"enrollment":508,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Skin Infections, Bacterial"],"interventions":[{"type":"DRUG","name":"Retapamulin Ointment, 1%","otherNames":["Retapamulin Ointment","1%"]},{"type":"DRUG","name":"Placebo ointment","otherNames":[]}],"arms":[{"label":"Retapamulin Ointment, 1%","type":"EXPERIMENTAL"},{"label":"Placebo Ointment","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.","primaryOutcome":{"measure":"Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population","timeFrame":"Days 12-14","effectByArm":[{"arm":"Retapamulin","deltaMin":184,"sd":null},{"arm":"Placebo","deltaMin":75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.098"}]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":54,"countries":["United States","Argentina","Brazil","India","South Africa"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":342},"commonTop":["Application site pain","Condition aggravated","Pyrexia"]}}